PROTAGONIST THERAPEUTICS INC
PTGXNASDAQTrading Snapshot
- Day Range
- $147.45 – $151.20
- 52-Week Range
- $50.49 – $151.60
- Volume
- $1.73B
- Avg Volume
- $2.26B
- Shares Outstanding
- 64.3M
- Next Earnings
- Sep 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $46M
- Last Q Revenue
- $213M
- P/E Ratio
- 115.4
- P/S Ratio
- 33.9x
- EPS (TTM)
- $1.04
- Dividend Yield
- —
Why Investors Own PTGX
- ✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PROTAGONIST THERAPEUTICS INC
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $145 to $170.
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $173
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $118 to $173.
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.
Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186
Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Buy and raises the price target from $110 to $186.
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $1.66 by 37.95 percent. This is a 516.36 percent increase over losses of $(0.55) per